IDYA IDEAYA Corp Company Short-Term Debt

IDEAYA Biosciences, Inc. - graphic logo of issuer IDYA

IDEAYA Biosciences' status as a leader in synthetic lethality is confirmed by historical short-term debt data, where the 0.00 mark serves as a current indicator. High R&D and patent protection costs create significant barriers to entry. Meanwhile, a stable capital reserve mitigates risks associated with the timelines of clinical trials for oncology drugs.

IDYA ideayabio.com Short-Term Debt (07/04/2022 - 10/29/2026)

Analytical breakdowns and data insights for company IDEAYA Corp (IDYA)

- current quotes and average value forecast:
Price Chart IDEAYA Biosciences, Inc.|IDYA - Average Forecast Price
- market capitalization data:
Market Value IDEAYA Biosciences, Inc.|IDYA - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share IDEAYA Biosciences|IDYA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio IDEAYA Biosciences|IDYA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio IDEAYA Biosciences|IDYA - Aggregate Debt Obligations|Debt to Book Value IDEAYA Biosciences, Inc.|IDYA - Amount of Long-Term Liabilities|Company Short-Term Debts IDEAYA Biosciences|Quick Liquidity ideayabio.com
- earnings and multiples data:
IDYA - Final Profit
General company analysis:IDEAYA Biosciences, Inc. - IDYA
Flagship merchandise of ideayabio.com

To protect capital from volatility, it is essential for investors to manage liquidity by assessing the total amount of liabilities maturing within one year. The integration of robotic screening in IDEAYA Biosciences (IDYA) laboratories optimizes molecule discovery costs, while the dynamics of short-term credit obligations allow these technological expenses to be weighed against current solvency, eliminating the risk of a cash crunch within the portfolio.

Who IDEAYA Biosciences competes with

GMAB - Company Short-Term Debt|Short-Term Debt Exelixis Inc|Nuvalent Corp (NUVL) - Company Short-Term Debt|KYMR (Kymera Corp) - Company Short-Term Debt|Company Short-Term Debt Enliven Therapeutics|Short-Term Debt oricpharma.com ORIC|Company Short-Term Debts RLAY|Nurix Therapeutics Inc (NRIX) - Short-Term Indebtedness|Tyra Bio - Company Current Liabilities|Verastem Corp (VSTM) - Short-Term Debt|GLUE: Company Current Liabilities|Company Short-Term Loans and Borrowings CGEM (cullinanoncology.com)|IMRX (Immuneering) - Company Current Liabilities|CCCC: Amount of Current Liabilities|BDTX (Black Diamond Therapeutics Inc.) - Company Short-Term Debts|Company Short-Term Debts Repare Therapeutics Inc|Company Short-Term Debt PMV Pharmaceuticals (PMVP)|KPTI (karyopharm.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts PPCB (Propanc Biopharma)|Short-Term Indebtedness Bio Green Med Solution Inc.|Aadi Bio - Company Short-Term Debts|Short-Term Debt Aileron Therapeutics|BPMC (blueprintmedicines.com) - Company Current Liabilities|GLYC: Amount of Current Liabilities|SWTX (SpringWorks Therapeutics, Inc.) - Company Short-Term Debts